Handelsman D J, Turtle J R
Diabetes. 1981 Jun;30(6):459-64. doi: 10.2337/diab.30.6.459.
A single-blind, nonrandomized, placebo crossover clinical trial of an aldose reductase inhibitor, Alrestatin (AY 22, 284) was performed over a 4-mo period in nine patients with diabetic peripheral neuropathy. Most patients had subjective benefit, but objective measures of conduction were essentially unchanged. Substantial toxicity was evident, particularly photosensitive skin rash.
对9例糖尿病性周围神经病患者进行了为期4个月的单盲、非随机、安慰剂交叉临床试验，以研究醛糖还原酶抑制剂Alrestatin（AY 22,284）的疗效。大多数患者有主观改善，但神经传导的客观指标基本未变。明显存在严重毒性，尤其是光敏性皮炎。
